Population Pharmacokinetics Age, gender, race, and renal and hepatic function were included as factors
MeSH terms
Therefore, use of sildenafil in patients with retinitis pigmentosa is not recommended. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including sildenafil. It is not possible to determine whether these reported events are related directly to the use of sildenafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors. Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including sildenafil. The safety and efficacy of combinations of sildenafil with VIAGRA or other PDE-5 inhibitors have not been studied.
5.4 Visual Loss
Inform patients taking sildenafil not to take VIAGRA or other PDE-5 inhibitors. In a small, prematurely terminated study of patients with pulmonary hypertension (PH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received sildenafil than by those randomized to placebo. The effectiveness and safety of sildenafil in the treatment of PH secondary to sickle cell disease has not been established. In a 12-week, placebo-controlled clinical study and an open-label extension study (SUPER-1) in 277 sildenafil-treated adults with PAH (WHO Group I) [see Clinical Studies (14)] the adverse reactions that were reported by at least 10% of sildenafil-treated patients in any dosing group, and were more frequent in sildenafil-treated patients than in placebo-treated patients are shown in Table 1. The overall frequency of discontinuation in sildenafil-treated patients was 3% (20 mg and 40 mg three times a day) and 8% (80 mg three times a day).
Warnings and Precautions
Most Common Adverse Reactions in Patients Treated with Sildenafil 20 mg, 40 mg, 80 mg and Placebo Three Times Per Day in SUPER-1 (More Frequent in Sildenafil-Treated Patients than Placebo-Treated Patients) In a placebo-controlled fixed dose titration study (PACES-1) of sildenafil (starting with recommended dose of 20 mg and increased to 40 mg and then 80 mg all three times a day) as an adjunct to intravenous epoprostenol in patients with PAH, no new safety issues were identified except for edema, which occurred in 25% of subjects in the combined sildenafil + epoprostenol group compared with 13% of subjects in the epoprostenol group [see Clinical Studies (14)]. In a study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH (StudyA1481324), the lower dose 5 mg TID group showed a higher observed number of deaths (all related to underlying disease/disease under study), serious adverse events, and severe adverse events than the 20 mg and 80 mg TID groups [see Clinical Studies (14)]. Sildenafil was studied in a total of 234 PAH pediatric patients 1 to 17 years of age in a 16-week, double-blind placebo-controlled study (STARTS-1); 220 patients continued in a long-term extension study (STARTS-2). Adverse events with sildenafil injection were similar to those seen with oral tablets. Concomitant use of sildenafil with nitrates in any form is contraindicated [see Contraindications (4)]. assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH.
Parameter
Details
Value
Absorption
Rapid, peak plasma levels in 30-120 min
Yes
Half-life
Time to reduce plasma concentration by half
3-5 hours
Metabolism
Liver via CYP3A4 enzyme
Primarily
Excretion
Mainly via feces, some via urine
Yes
Pediatric Patients Body weight was shown to be a good predictor of drug exposure in children.
Product
Dosage
Quantity + Bonus
Price
Kamagra
100mg
360 + 6 Pills
839.95€ 799.95€
Viagra Generic
50mg
180 + 8 Pills
158.82€ 151.26€
Kamagra Polo
100mg
120 + 6 Pills
327.15€ 311.57€
Viagra Generic
50mg
20 Pills
40.52€ 38.59€
Kamagra Oral Jelly
100mg
220 + 18 Sachets
662.24€ 630.70€
Viagra Generic
50mg
10 Pills
26.87€ 25.59€
Viagra Generic
50mg
60 + 4 Pills
83.93€ 79.93€
Kamagra Soft Tabs
100mg
272 + 12 Pills
593.42€ 565.16€
Kamagra
100mg
120 + 6 Pills
330.74€ 314.99€
Kamagra
100mg
32 Pills
121.24€ 115.47€
Viagra Generic
100mg
10 Pills
28.91€ 27.53€
Viagra Generic
200mg
20 Pills
61.69€ 58.75€
In volunteers with severe (CLcr less than 30 mL/min) renal impairment, sildenafil clearance was reduced,
Sildenafil tablets 125 mg can be part of a broader ED treatment plan.
Psychological counseling may enhance effectiveness.
Combining therapies can improve outcomes.
Lifestyle modifications include weight management and exercise.
Quitting smoking can improve erectile health.
Vasodilator drugs should be avoided when using sildenafil.
Maintain a balanced diet alongside medication.
Support groups can offer additional assistance.
resulting in approximately doubling of AUC and Cmax
Description for Viagra
Concomitant use of sildenafil with strong CYP3A inhibitors is not recommended [see Clinical Pharmacology (12.3)]. Concomitant use of sildenafil with moderate-to-strong CYP3A inducers (such as bosentan) decreases the sildenafil exposure. Dose up-titration of sildenafil may be needed when initiating treatment with moderate-to-strong CYP3A inducers. Reduce the dose of sildenafil to 20 mg three times a day when discontinuing treatment with moderate-to-strong CYP3A inducers [see Clinical Pharmacology (12.3) and Clinical Studies (14)]. Animal reproduction studies conducted with sildenafil showed no evidence of embryo-fetal toxicity or teratogenicity at doses up to 32- and 65-times the recommended human dose (RHD) of 20 mg three times a day in rats and rabbits, respectively (see Data).
Clinical monitoring
No evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed in pregnant rats or rabbits dosed with sildenafil 200 mg/kg/day during organogenesis, a level that is, on a mg/m2 basis, 32- and 65-times, respectively, the recommended human dose (RHD) of 20 mg three times a day. In a rat pre- and postnatal development study, the no-observed-adverse-effect dose was 30 mg/kg/day (equivalent to 5-times the RHD on a mg/m2 basis). Limited clinical data during lactation preclude a clear determination of the risk of sildenafil to an infant sildenafil pricing during lactation. The safety and efficacy of sildenafil have been established in pediatric patients 1 to 17 years old, for the treatment of PAH (WHO Group I) to improve exercise ability and, in patients too young to perform standard exercising testing, pulmonary hemodynamics thought to underlie improvements in exercise. Use of sildenafil for this indication is supported by evidence from adequate and well-controlled studies in adults with additional PK and safety data in pediatric patients aged 1 year and older [see Adverse Reactions (6.1), Clinical Studies (14)].
Dosage for erectile dysfunction (ED)
The safety and effectiveness of sildenafil have not been established in pediatric patients younger than 1 year of age. During the conduct of the pediatric studies (STARTS-1 and STARTS-2) [see Clinical Studies (14)], an imbalance in the number of deaths was noted: 5/55 (9.1%), 10/74 (13.5%), and 22/100 (22%) in the sildenafil low, medium, and high dose groups, respectively. Given the beneficial effects on clinical worsening and death observed in adults with increasing doses (Study A1481324) and the expected similarity of disease in pediatrics and adults, a causal association for the observed dose-related effect on mortality in pediatric patients is unlikely, and therefore, the available data support dosing in pediatric patients > 45 kg up to a maximum of 40 mg three times a day. Clinical studies of sildenafil did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)]. compared to age-matched volunteers with no renal impairment.
Proper Use
An evaluation of visual function at doses up to 200 mg revealed no effects of sildenafil on visual acuity, intraocular pressure, or pupillometry. Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25 to 63%). When sildenafil is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. Sildenafil Injection: The pharmacokinetic profile of sildenafil has been characterized following intravenous administration. A 10 mg dose of sildenafil injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200% and 79%,
Sildenafil use should be disclosed to your healthcare provider.
Not suitable for men with severe cardiovascular conditions.
Ask about possible drug interactions before starting.
Adjustments may be needed for older adults.
Timing of medication is important for maximum effect.
Monitoring for side effects helps prevent complications.
Stop using sildenafil if health issues arise.
Always follow professional medical advice.
respectively, in patients with severe renal impairment compared to patients with normal renal function.
2.3 Dosage Adjustments in Specific Situations
Severe impairment has not been studied [see Clinical Pharmacology (12.3)]. No dose adjustment is required (including severe impairment CLcr < 30 mL/min) [see Clinical Pharmacology (12.3)]. Sildenafil for oral suspension is supplied as white to off-white granular powder containing 1.57 g of sildenafil citrate USP (equivalent to 1.12 g sildenafil) in an amber PET bottle intended for reconstitution. Following reconstitution with 90 mL water, the volume of the oral suspension is 112 mL and the oral suspension contains 10 mg/mL sildenafil. In addition to the bottle, a press-in bottle adapter and an oral dosing syringe (with 1 mL and 2 mL dose markings) are provided.
Is Viagra dosage based on age or weight?
This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]. Patients on all sildenafil doses achieved a statistically significant reduction in mean pulmonary arterial pressure (mPAP) compared to those on placebo in a study with no background vasodilators [see SUPER-1 in Clinical Studies (14)]. Data on other hemodynamic measures for the sildenafil 20 mg three times a day and placebo dosing regimens is displayed in Table 2. Patients on sildenafil medium and high dose groups achieved dose related improvements in pulmonary vascular resistance index (PVRI) and mean pulmonary arterial pressure (mPAP) compared to those on placebo [see STARTS-1 in Clinical Studies (14)]. Improvements were observed with cardiac index in all three sildenafil dose groups sildenafil citrate chewable tablets over placebo.
12.1 Sildenafil Oral Suspension Mechanism of Action
Data on other hemodynamic measures for the sildenafil low, medium and high dose groups compared to placebo is displayed in Table 3. Single oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]. After chronic dosing of 80 mg three times a day sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9 mmHg and 8.4 mmHg, respectively. After chronic dosing of 80 mg three times a day sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 and 9.1 mmHg, respectively.